P. ariasi polypeptides, p. perniciosus polypeptides and methods of use

US7741437B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Department of Health and Human Services · US
• MERIAL INC. · US

Inventors

• Jesus G. Valenzuela · Gaithersburg, US
• Jose M. C. Ribiero · Rockville, US
• Shaden Kamhawi · Rockville, US
• Yasmine Belkaid · Norwood, US
• Laurent Fischer · Sainte-Foy-lès-Lyon, FR
• Jean-Christophe Audonnet · Val-de-Reuil, FR
• Francis Milward · Montbrison, FR

Key dates

• Filing date: Sep 18, 2003
• Grant date: Jun 22, 2010
• Expiry date: Mar 3, 2026

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Substantially purified salivary P. ariasi and P. perniciosus polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the P. ariasi and P. perniciosus polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments, methods for treating or preventing Leishmaniasis are disclosed.